Market Report Source

Overview

The area of drug discovery tools is one of the newest and most important sectors of pharmaceutical research and development. The term drug discovery tools usually refers to high-content screening (HCS) and analysis and is composed of those applications that require sufficient levels of sample throughput, whereby complex cellular events and phenotypes can be studied. Elements of drug performance like toxicity and specificity can be established simultaneously using mixed cell types-primary cells, cell lines, cell subpopulations. HCS seeks to assess the impact of phenotypic and cellular changes that are brought about by gene modification (such as with RNA interference (RNAi) approaches) and/or drug (or compound) treatment.

The purpose of this examination by TriMark Publications is to describe the specific segments of the global drug discovery tools market. Within this area, the report covers those segments that are highly active in terms of innovation and growth. Specifically, this study examines the markets for small lab equipment all the way up to highly automated, large automated platforms, as well as accessory equipment such as reagents, supplies and manufacturers’ original equipment manufacturer (OEM) additional equipment.

Table of Contents

1. Overview
1.1 Objectives of the Report
1.2 Methodology
1.3 Scope of the Report
1.4 Executive Summary

2. Technologies and Product Offering for HCA
2.1 Definition of HCA and Why it is so Attractive a Discipline
2.2 Classes of Measurements Possible with HCA Approaches and Biologies Interrogated
2.3 Instrumentation Platforms for HCA
2.4 Reagent and Assay Platforms for HCA
2.5 Cell-based Screening Technologies in Drug Development
2.5.1 Applications of Cell-based Assays
2.5.2 Pharma Drug Discovery Paradigm and Compound Screening
2.5.3 HCA in the Biopharmaceutical Industry

3. Market Analysis of the High-Content Tools Space
3.1 HCA Market Size and Growth
3.2 Market Survey to Assess Qualitative and Quantitative Parameters of the HCA Space
3.3 Experimental and Research Trends in HCA
3.4 Challenges and Market Drivers in HCA
3.4.1 Barriers to HCA
3.4.2 Drivers of HCA
3.5 HCA in Combination with RNAi
3.6 Market Landscape of Instrumentation for HCA
3.7 Reagents and Assays Usage in HCA
3.8 Trends in HCA Assays/Reagents Space-Major Product Vendors
3.9 Emerging Market Trends in HCA
3.10 Market Forecasts for the HCA Space
3.11 Use of HCS in Pharmaceutical Companies
3.12 Qualitative Opportunities and Challenges for Market Adoption

4. Strategic Analysis of the High-Content Tools Space
4.1 HCA Market Structure
4.2 Description of the Drug Discovery Marketplace and Definition of the Field
4.3 Key Market Drivers and Challenges in the HCA Space
4.4 Consolidated Picture of the HCA Marketplace
4.5 HCA Market Sectors and Growth Rate
4.6 Vendors of HCA Technology

5. HCA Technology Platforms
5.1 Methods of Digital Imaging
5.2 Fluorescence Microscopy
5.3 Major HCA Instrumentation
5.4 HCA Reagents
5.5 Imaging Software
5.6 Image Analysis Algorithms
5.7 Use of RNAi in HCA
5.8 Industry Alliance to Leverage RNAi and HCA
5.9 Emerging Trends in HCA Technology Platforms

6. HCA in Drug Selection and Screening
6.1 Stem Cells Used as a Drug Discovery Tool
6.2 Drug Discovery Companies Marketing Cell-based Assays

7. Company Profiles and Glossary of Terms in HCA
7.1 Acumen Pharmaceuticals, Inc.
7.2 Applied Biosystems
7.3 Becton, Dickinson and Company
7.4 Beckman Coulter, Inc.
7.5 Blueshift Biotechnologies, Inc.
7.6 Caden Biosciences, Inc.
7.7 Cellomics, Inc.
7.8 Cellumen, Inc.
7.9 Cenix BioScience
7.10 Cyntellect
7.11 Definiens
7.12 DiscoveRx
7.13 Euroscreen
7.14 Evotec Technologies
7.15 Fisher BioImage
7.16 General Electric
7.17 Guava Technologies, Inc.
7.18 Millipore
7.19 Molecular Devices Corporation
7.20 NIH Chemical Genomics Center
7.21 PerkinElmer
7.22 Spotfire
7.23 Translational Genomics Research Institute
7.24 Vala Sciences, Inc.

8. Glossary of Terms in the HCA Space

LIST OF FIGURES

Figure 2.1: Scope of Biological Parameters Addressed via a Typical HCA Experiment
Figure 2.2: Classes of Assays in Life Science Research and Drug Discovery Illustrating the Relationship between Cell-based Assays and HCA
Figure 2.3: New Paradigm of Drug Discovery and Development Illustrating the Central and Essential Role of Screening
Figure 2.4: Cumulative and New Drug Targets
Figure 3.1: Breakout of Market Survey Respondents by Geographical Location
Figure 3.2: Breakout of Market Survey Respondents by Affiliation-Academic, Commercial, Vendor
Figure 3.3: Segmentation of Respondent Pool based upon Usage of HCA in its Research Activities
Figure 3.4: Segmentation of the Survey Respondent Pool based upon the Length of Time they have been Using HCA in their Research Activities
Figure 3.5: Number of Parameters Studied Simultaneously in HCA Assays-Multivariate [Multi-Parameter] Analyses
Figure 3.6: Key Biological Processes Studied Utilizing HCA Tools
Figure 3.7: Breakout of HCA Assays Currently Performed or Expected to be Performed in the Future by Biological Pathway (or Target)
Figure 3.8: Breakout of HCA Experiments Performed Per Week (Distributed in our Respondent Pool) Across the Various Biological Pathways (and Targets)
Figure 3.9: Which of the Biologies (Pathways/Targets) Addressed Using HCA-based Approaches are Growing in Importance or Declining?
Figure 3.10: In Which Environment are HCA Assays Performed-Primary Screen, Secondary Screen, ADME/Tox Screen?
Figure 3.11: Key Challenges Faced by the Research Community in Their Practice of HCA
Figure 3.12: Various Drivers that are Leading the Research Community to Perform HCA
Figure 3.13: HCA Together with RNAi-Current and Future Experimental Formats
Figure 3.14: HCA Together with RNAi-Number of Experiments Performed Per Month by the Survey Respondent Pool
Figure 3.15: Growing and Steady Usage of the Various Formats where RNAi is coupled with HCA
Figure 3.16: Penetration of the Different HCA Instrumentation Platforms into the Marketplace
Figure 3.17: Instrumentation Platforms for HCA Ranked by Top Choice and Second Tier
Figure 3.18: HCA Instrumentation and where they lie on the Throughput Curve
Figure 3.19: Top Instrumentation Value Drivers in the HCA Space
Figure 3.20: Important Sub-Cellular Features Studied via HCA Approaches
Figure 3.21: Breakout of End-Point versus Kinetic Assays in the HCA Space
Figure 3.22: Types of Cellular Targets Studied Using HCA Approaches
Figure 3.23: Top-most Target Class Being Studied Utilizing HCA Approaches
Figure 3.24: Distribution of HCA Experiments across the Respondent Pool-Number of Experiments Performed Per Week
Figure 3.25: Average Reagent/Assay Costs Per HCA Experiment
Figure 3.26: Stratification of Reagent/Assay Suppliers into the HCA Space
Figure 3.27: Monthly Reagent/Assay Purchases for HCA by the End-User Community from the Various Vendors Offering Products into the Space
Figure 3.28: Growth or Decline in Importance of the Various HCA Vendors to the End-User Community
Figure 3.29: Percentage of HCA Experiments that Involve GFP across the Market Landscape
Figure 3.30: Breakout of HCA Reagents Marketplace: Home-Brew Versus Off-the-Shelf
Figure 3.31: Breakout of Spending into the Various Components of the HCA Discipline
Figure 3.32: Forecast Growth of the Total Screening Space-Broken-out by Primary Screening, Secondary Screening (Includes HCA as a Subset) and ADME/Tox
Figure 3.33: Forecast Growth of the Screening Space-Broken-out by Cell-based Assays and Biochemical Assays
Figure 4.1: Drug Discovery and Development Ensemble and the Position of the Various Segments of HCA in the Space
Figure 4.2: Relative Size and Position of the HCA Space in the Overall Scheme of the Life Science Tools Marketplace
Figure 5.1: HCA: Positional Biosensors Using Caspases and Monitoring the Translocation of a Tagged Protein from the Cytoplasm to the Nucleus
Figure 6.1: Druggability of the Various Target Classes: Breakout of the Drug Targets Today into their Constituent Classes
Figure 6.2: GPCR Assay Technologies

LIST OF TABLES

Table 2.1: Comparison of the Key Features of HCA and HCS
Table 2.2: Impact of HCA on Drug Discovery-Several Drivers are Addressed
Table 2.3: Biological Application Areas Associated with HCA
Table 2.4: Classes of Measurements and Targets Identified Using Phenotypic Screening (HCA)
Table 2.5: Classes of Cellular Measurements Possible with Fluorescent Protein Biosensors
Table 2.6: Multi-Parameter HCA Assays to Study Biological Systems in Life Science Research and Drug Discovery-Demonstrates the Breadth and Scalability of the HCA Approach
Table 2.7: Companies Offering Systems for High-Throughput Imaging
Table 2.8: Comparison of the Major Instrumentation Platforms and their Associated Specifications for HCA-I
Table 2.9: Comparison of the Major Instrumentation Platforms and their Associated Specifications for HCA-II
Table 2.10: Price Points and Target Markets of the Various HCA Instrument Platforms
Table 2.11: Companies Offering Flow Cytometry Products and Services
Table 2.12: Integrated Product Platforms Offered by the Different HCA Vendors
Table 2.13: Biologies interrogated by Cellomics HCA Assays
Table 2.14: Cellomics HitKit® HCA Assay/Reagent Kits and the Therapeutic Areas Where They Find Application
Table 2.15: Assay/Reagent Portfolio of Millipore Addressing HCA Applications
Table 2.16: Cell Lines for GPCR HCA that can be Deployed onto the BD Biosciences/Atto Pathway HT™ Instrument Platform
Table 2.17: Examples of High Content Screens
Table 3.1: What Fraction of HCA Assays are Cell-based Versus Biochemical-based
Table 4.1: Comparison of the Key Features of HCA and HCS
Table 4.2: Snapshot of the Various HCA Assays Demonstrating the Scalability of this Discipline
Table 5.1: Modes of Digital Imaging
Table 5.2: Modes of Fluorescence
Table 5.3: Major HCA Instrumentation
Table 5.4: Image Analysis Algorithms